Navigation Links
Patheon to Feature its Complex Formulation Technologies Expertise at the Upcoming CPhI – P-MEC –ICSE – BioPh – Pharmatec – Medtec Japan – Conference
Date:4/14/2013

(PRWEB) April 14, 2013

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, will feature its wide range of complex formulation technologies for small molecules and biologics at the upcoming CPhI/ICSE conference in Tokyo, Japan.    

Dr. Kenji Yamada, Patheon, Advisor, will present “The Introduction of the Services of SoluPath™ and Quick to Clinic™” at 2:30 p.m. Japan Standard Time on April 26, 2013. SoluPath™ is an innovative and cost-effective service used to identify an optimal drug delivery system for compounds with poor bioavailability. In a recent case study, SoluPath™ improved bioavailability by four times in just three months. The Quick to Clinic™ program offers an accelerated delivery of Phase I clinical trial materials, guaranteeing finished product within four months of receipt of API.    

Patheon personnel will be at the upcoming CPhI/ICSE conference in Tokyo, Japan from April 24-26, 2013 and available to discuss how the company can actively support pharmaceutical and biotech companies achieve their objectives for both product development and manufacturing. The company will be exhibiting at Booth J-04 through the duration of the conference. To schedule a meeting in advance send an email to events(at)patheon(dot)com.

For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx.

About Patheon

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.

Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 18 locations, including 14 commercial contract manufacturing facilities and 12 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit http://www.patheon.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10626742.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
2. Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility
3. Patheon to Present at Informex USA
4. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
5. Patheon to Present at 2013 DCAT Week
6. Patheon to Present New Updates in Drug Formulation and Bioavailability
7. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
8. Patheon to Showcase High Potency Capabilities at Upcoming Tradeshows
9. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
10. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
11. Ellmans Pelleve™ Wrinkle Reduction System featured in "Sexy Eyes" segment on The Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... ... cuvettes are used in leading laboratories all over the globe. Their cute firefly ... addition to manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never require ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Ankle ... plating options designed to address fractures of the distal tibia and fibula. This ... Acumed Ankle Plating System 3 is composed of seven plate families that span ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens ... for mesothelioma may be hampering the research that could lead to one good one. ... to read it now. , The team evaluated 98 mesothelioma patients ...
(Date:5/25/2016)... Connecticut (PRWEB) , ... May 25, 2016 , ... ... the U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug ... the company’s second orphan drug designation granted by the FDA. , Spinocerebellar ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):